根据湖南公众资产评估有限公司2022年4月12日出具的资产评估报告，截至2021年底，太子奶共有员工 88人，合计房屋建筑面积11.16万平方米。由于设备老化，生产线跑冒滴漏严重，导致无法组织生产， 太子奶从2020年8月至今生产区无生产，设备处于停用状态，自同年9月起全线产品委托在外加工。公司 生产区约有1万平方米厂房对外租赁，其余厂房均处于未使用的闲置状态。评估报告还显示，太子奶集 团现无在生产区恢复生产的计划，生产设备将逐步处置。 2021年8月，新华联持有的太子奶40%股权在淘宝网司法拍卖网络平台进行拍卖，其评估价为1.52亿 元，起拍价为1.06亿元，但该次拍卖被湖南省株洲市中级人民法院来函中止。今年7月，太子奶40%股 权的拍卖重启，该股权评估价为1.25亿元，起拍价为8756.76万元，但最终却无人报名，大股东三元股份 也放弃优先购买权且不参与拍卖。 时隔一个月后，太子奶40%股权的起拍价降至7005.40万元。根据淘宝网司法拍卖网络平台显示，本次 拍卖的报名方仅有1家，即为三元股份。 业绩承压 三元股份8月7日公告称，8月6日10时至8月7日10时，北京市第三中级人民法院在淘宝网司法拍卖网络平 ...

Market Overview - A-shares experienced a strong opening in June, with all three major indices rising and over 3,300 stocks in the market showing gains [1] - The Shanghai Composite Index rose by 0.43%, the Shenzhen Component increased by 0.16%, and the ChiNext Index gained 0.48% [1] - The total market turnover reached 1.16 trillion yuan [1] Key Sectors - The sectors that performed well included the China-South Korea Free Trade Zone, new consumption, football concepts, precious metals, and pharmaceuticals [1] - The rare earth permanent magnet sector saw significant gains, with Guangsheng Nonferrous Metals hitting the daily limit and reaching a new high [12] Notable Stocks - Junyao Health, known as the "first stock of room temperature lactic acid bacteria," achieved a remarkable performance with six consecutive trading days of gains, including a daily limit increase [2][5] - The stock's trading volume exceeded 800 million yuan [2] - Innovative drug stocks remained active, with Shutaishen hitting the daily limit and a cumulative increase of 188.04% since May 20 [7][9] Company Performance - Junyao Health reported a production volume of approximately 85.99 million liters for probiotic products in 2024, a year-on-year increase of 3.54%, while sales volume decreased by 1.41% to about 83.99 million liters [5] - The sales revenue for probiotic products was approximately 595 million yuan, down 2.71% year-on-year [5] Innovative Drug Sector - The innovative drug sector is gaining attention, with the approval of 11 new innovative drugs by the National Medical Products Administration [10] - The sector is expected to benefit from ongoing policy support and international licensing agreements, enhancing growth prospects for related companies [10] - Shutaishen's subsidiary is under scrutiny for its drug application, which may impact future evaluations [9] Conclusion - The overall market sentiment is positive, with a focus on growth sectors such as technology and consumer-driven industries, alongside stable sectors like banking [15]